We scan new podcasts and send you the top 5 insights daily.
Ben Isaac says relisting to the US is not just multiple arbitrage. He says it can make management pay competitive, give companies equity to retain talent, change the shareholder base, and improve liquidity, all of which affect how the business operates in really tangible ways.
The rationale for an IPO has shifted. Companies can now offer employee liquidity through structured secondaries, a key historical benefit of going public. This allows them to avoid the downsides of being public, namely the impact of daily stock volatility on employee morale and the pressure from short sellers.
Beyond providing liquidity and raising a firm's profile, becoming a publicly listed company can give employees a tangible "spring in the step." The ability to see a daily share price and feel part of a growing, visible entity creates a powerful sense of engagement that is often underestimated.
The European biotech's US listing strategy is threefold: to be present in its primary commercial market, to offer stock options to attract and retain specialized American talent, and to access a deeper pool of specialist investors that is unavailable in Europe's fragmented public markets for growth companies.
Running a public company today is so arduous that founders require extraordinary incentives to stay. Massive, equity-heavy compensation packages, like those for Elon Musk or proposed at Revolut, are less about greed and more about making the pain of public market scrutiny worthwhile for founders who could otherwise remain private.
Bill Ackman's plan for Universal Music Group shows that simply changing a stock's listing to a major market like the U.S. can unlock immense value. Access to indexes like the S&P 500 forces automatic buying from funds, tapping into a huge investor base without altering the company's core operations.
GenFit's CEO reveals a fluid capital markets strategy. The company delisted from US exchanges due to high costs and low news flow but is now considering a return as its pipeline advances. This demonstrates that a public listing is viewed as a strategic option to be utilized when conditions are optimal, not a permanent necessity.
Pouletty warns that while a NASDAQ listing provides capital, it often leads to US investor pressure to replace European leadership with American executives. This shift in management can change the company's culture and center of gravity, ultimately making it an American company that is more easily acquired by US pharma giants.
iCapital's CEO argues against rushing to an IPO, citing the distraction of stock volatility. To retain employees who hold equity, the private company provides periodic opportunities for them to sell a limited portion of their holdings. This balances the need for liquidity with the benefits of staying private.
NervGen's new CEO identified that being on the Toronto Stock Exchange kept the company in "anonymity." A key strategic move was uplisting to NASDAQ to gain visibility with U.S. analysts and institutional investors, recognizing that being on the right exchange is a critical marketing and fundraising tool.
Ben Isaac says among 30-plus real businesses that relisted to the US public markets over five years, it is hard to find ones that did not materially re-rate and hold it. Importantly, he adds, their liquidity grew even more than valuation on average over time.